HIV history of treatment failure and no known substitutions associated with resistance to the individual components. emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate EXTENDED RELEASE TABLETS 150 mg/300 mg , An osmotic system is disclosed comprising a wall comprising in at least a part of a semi permeable material that surrounds a compartment . the compartment contains an osmotic composition comprising a beneficial drug selected from the ·group consisting emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate and second different osmotic composition a passageway in the wall connects the fist composition with the exterior of the system. Extended release tablets a unique osmotic drug delivery system are similar appearance to the conventional tablets. They consistent of semi permeable membrane surrounding an osmotically active drug core .the core is divided in to two layers active containing drug layer and push layer containing pharmacologically inert (but osmotically active) components. as water from gastrointestinal tract enters the tablet ,pressure increase in the osmotic layer and pushes against the drug layer releasing drug through the precision laser drilled tablet orifice in the active layer because of the ability to deliver a constant and uniform dose emtricitabine, rilpivirine hydrochloride, ana tenofovir alafenamide fumaratetablets.
